Blood tests to tell cancerous from harmless lung nodules
Studies blood markers to help judge whether a lung nodule is cancer.
Plain-language title generated from the registry record
Registry title: Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
Key facts
- Where
- Gentofte Municipality, DenmarkSee the site
Where in Denmark
- Gentofte HospitalGentofte Municipality, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Herlev and Gentofte Hospital
- Trial code
- NCT07623473
- Record updated
- 3 June 2026
- Original description
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.Read full original descriptionShow less
NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.
Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
Inclusion: Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit; Having signed informed consent.
Exclusion: Active cancer, excluding non-melanoma skin cancer; Comorbidities that exclude the patient from clinical follow-up and final diagnosis.